Tuesday, September 9, 2025

New digital therapy: attexis® expands treatment options for adults with ADHD and is now permanently reimbursed by health insurers

Since August 6, 2025, all statutory health insurers and many private insurers have been covering the costs of attexis®, the first permanently listed digital health application (DiGA) for adults with ADHD. With this, MEDICE – Europe’s market leader in ADHD – is further expanding its wide range of treatment options.

attexis® offers patients aged 18 and over individualized digital support for daily life – focusing on daily structuring, symptom management, and strengthening self-organization in line with S3 guidelines.

The program includes six interactive therapeutic dialogues tailored to the patient’s individual needs and adaptable as therapy progresses. Weekly reflections and progress overviews boost motivation and make developmental steps visible. Practical tools such as planners, checklists, and audio exercises support everyday implementation and promote lasting change.

“We want to offer adults an additional, targeted digital therapy – especially considering the often long waiting times for therapy slots. With attexis®, we expand the possibilities for continuous and multimodal treatment,” explains Dr. Katja Pütter-Ammer, Managing Partner at MEDICE.

Evidence-based efficacy
The clinical efficacy of attexis® was confirmed in a randomized controlled trial. Use of attexis® in addition to standard treatment led to a significant reduction in core ADHD symptoms. Secondary outcomes such as social and occupational functioning, quality of life, depressive symptoms, and self-esteem also improved significantly.

Thus, attexis® provides not only patients but also physicians with a new evidence-based and resource-friendly option in multimodal ADHD treatment.

“The permanent approval of attexis® is a milestone in the care of adults with ADHD. For the first time, patients and healthcare providers gain permanent access to a digital therapy with proven efficacy and broad benefits for care,” emphasizes Dr. Mario Weiss, CEO of GAIA, developer of attexis®.

With this innovation, MEDICE continues to strengthen its pioneering role in digital healthcare – after the recent launch of hiToco® for parents of children with ADHD, now also for adult patients.